The brain is protected from pathogens and certain molecules by the blood-brain barrier, complicating the development of effective drugs for diseases like brain cancers.
TheraSonic, a startup based on more than 15 years of research at CEA Saclay and CNRS, develops a medical device using transcranial focused ultrasound to make this barrier permeable to drugs and allow for their delivery. This non-invasive medical device, combining a robotic arm and a neuronavigation system, precisely targets areas of the brain, opening new perspectives for treating brain metastases. A patented ultrasonic dosimetry system ensures the device’s safety.
M2care has been working alongside the scientific team for several months prior to Therasonic’s launch and is now investing financial and human resources to progress the company’s goals of finding a solution for patients with brain metastases.
